Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Drugs that treat HIV trialled in people with multiple brain tumours

Professor Oliver Hanemann is leading the clinical trial involving 12 people (Brain Tumour Research Centre/University of Plymouth/PA)
Professor Oliver Hanemann is leading the clinical trial involving 12 people (Brain Tumour Research Centre/University of Plymouth/PA)

Drugs that treat HIV are being trialled for the first time in people with multiple brain tumours, for which there is no current cure.

Scientists believe the already-approved medicines ritonavir and lopinavir could shrink tumours in people with neurofibromatosis 2 (NF2), a genetic condition which causes tumours to grow along nerves.

While usually non-cancerous, NF2 can cause symptoms such as loss of balance, hearing loss that gradually gets worse over time and ringing in the ears.

If tumours grow inside the brain or spinal cord or along the nerves of the arms and legs, people can suffer limb weakness and persistent headaches.

The new clinical trial on 12 people, led by Professor Oliver Hanemann at the Brain Tumour Research Centre of Excellence at the University of Plymouth, will build on lab studies showing the HIV and Aids drugs can slow down and shrink NF2 tumours.

Previous research has also shown promise in using the drugs for other types of brain tumour.

There are no current treatments for NF2, which affects about one in 25,000 to 40,000 people, other than surgery.

Prof Hanemann said: “This could be the first step towards a systemic treatment for tumours related to NF2, both for patients who have inherited NF2 and developed multiple tumours, as well as patients who have a one-off NF2 mutation and have developed a tumour as a result.

“If results are positive and the research develops into a larger clinical trial, it would be the most significant change for patients with this condition, for whom there is no effective treatment.”

During the year-long trial, patients will undergo a tumour biopsy and blood test before having 30 days of treatment with the two medicines.

Jayne Sweeney lies in a hospital bed as an 18-year-old in 2001
Jayne Sweeney, who is now 57, when she was 18 in 2001 (Brain Tumour Research Centre/University of Plymouth/PA)

They will then have another biopsy and blood test to see whether the drugs have managed to enter tumour cells and shrink the tumours.

Dr Karen Noble, director of research, policy and innovation at Brain Tumour Research, said: “What is great about using repurposed drugs such as ritonavir and lopinavir is that they have already been shown to have a strong safety profile in healthy people and those treated for HIV, which means that they can more quickly be translated from the laboratory to patients.”

Jayne Sweeney, 57, from Mevagissey, Cornwall, was diagnosed with NF2 in 1996.

She has 12 tumours growing in her brain and has had five operations to remove tumours from her brain, ear and ankle.

Mrs Sweeney said: “The Retreat trial is incredibly exciting – any advancement to improve people’s lives is brilliant.

“A cure for NF2 is too late for me, but I am extremely proud to have been invited on to the trial steering group where I have seen first-hand just how passionate the team is about helping people with this disease.

“If we can find an effective drug for people newly diagnosed, that would be fantastic.

Mark Sweeney and Jayne Sweeney smile at the camera in a coastal setting
Mark Sweeney and Jayne Sweeney, 57, who has lived with Neurofibromatosis 2 since her diagnosis in 1996 (Brain Tumour Research Centre/University of Plymouth/PA)

“For me, the loss of hearing is the worst thing about having NF2 because it’s very isolating and frustrating.”

Mrs Sweeney has undergone 15 months of chemotherapy and Gamma Knife surgery, with painful injections into her head.

“Finding better and kinder ways to treat the disease is so important,” she said.

In half of all cases of NF2, the faulty gene is passed from a parent to their child.

If either the mother or father has the faulty gene, there is a 50% chance that each child they have will develop NF2.

In other cases, the faulty gene appears to develop spontaneously but it is not known why this happens.

Most people with NF2 eventually develop significant hearing loss and the condition worsens over time.